BCR-ABL-IN-13

Overview

BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a K i value of 0.55 μM against c-Src , 0.10 μM against wild-type Abl , and 0.40 μM against the Abl T315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant Abl T315I mutant. BCR-ABL-IN-13 can be used for the research of chronic myeloid leukemia.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer | Products > Signaling Pathways > Src | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-112404
• CAS No.: 607702-99-8
• Molecular Formula: C16H11F2N3OS2
• Molecular Weight: 363.40
• Purity: 99.86%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.08 mg/mL (5.72 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source